Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2020, with a specific reporting date of April 16, 2020. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on April 14, 2020.
| Instrument | Transaction Price | Exchange |
|---|---|---|
| Ordinary Shares (GBP) | £15.4420 | London Stock Exchange (XLON) |
| American Depositary Shares (USD) | $38.8800 | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine increases in notional interest in shares held by executives within the Company's Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described are automatic re-investments of dividends paid to shareholders on April 9, 2020, rather than discretionary market trades.
Important Facts for Investors
- Transaction Nature: All reported transactions were automatic dividend re-investments under the Deferred Annual Bonus Plan, not open-market purchases or sales.
- Participants: Transactions involved 15 senior executives, including the CEO (Ms E Walmsley), CFO (Mr I Mackay), and Chief Scientific Officer (Dr H Barron).
- Timing: All transactions occurred on April 14, 2020, following the dividend payment date of April 9, 2020.
- Volume: Individual transaction volumes were relatively small, ranging from 33 to 970 shares/ADSs per executive.
- Financial Data: This filing provides no data on GSK's overall financial health, revenue, or earnings for the period.